Difficulty: Medium
Average Score: 87%
Practice
A 58-year-old woman with multiple sclerosis presents to her primary care physician for follow-up. She ambulates well and has few issues with her disease. Which of the following agents may be beneficial in slowing the progression of this disease?
Correct answer
B
Rationale
The correct answer is option B) Fingolimod. Fingolimod is a disease-modifying drug used in the treatment of multiple sclerosis. It works by trapping immune cells in the lymph nodes, preventing them from reaching the central nervous system and causing inflammation and damage. By slowing down the immune response, Fingolimod helps in reducing the progression of multiple sclerosis and preventing relapses.
Option A) Dalfampridine is used to improve walking in patients with multiple sclerosis but does not slow down the progression of the disease.
Option C) Mitoxantrone is an immunosuppressant and antineoplastic agent that is used in aggressive forms of multiple sclerosis but is associated with significant risks and side effects.
Option D) Vitamin A does not have a proven benefit in slowing the progression of multiple sclerosis.
Educationally, understanding the mechanism of action of different drugs used in the treatment of multiple sclerosis is crucial for healthcare professionals to make informed decisions in managing patients with this condition. It is essential to differentiate between symptomatic treatments like Dalfampridine and disease-modifying treatments like Fingolimod to provide the best possible care for patients with multiple sclerosis.
Option A) Dalfampridine is used to improve walking in patients with multiple sclerosis but does not slow down the progression of the disease.
Option C) Mitoxantrone is an immunosuppressant and antineoplastic agent that is used in aggressive forms of multiple sclerosis but is associated with significant risks and side effects.
Option D) Vitamin A does not have a proven benefit in slowing the progression of multiple sclerosis.
Educationally, understanding the mechanism of action of different drugs used in the treatment of multiple sclerosis is crucial for healthcare professionals to make informed decisions in managing patients with this condition. It is essential to differentiate between symptomatic treatments like Dalfampridine and disease-modifying treatments like Fingolimod to provide the best possible care for patients with multiple sclerosis.